Need Help?

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

ABACUS is a single arm phase 2 study that investigated 2 cycles of atezolizumab (1200mg Q3) prior to cystectomy in 95 patients with muscle invasive transitional cell cancer (T2-4N0M0). Pathological complete response (pCR) occurring in ≥20% of patients was the primary endpoint. Biomarker analysis on sequential tissue was a co-primary endpoint.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001006199 -
EGAD00001006200 -
EGAD00001006201 -
EGAD00001006205 Illumina HiSeq 2500 148
EGAD00001007578 -
EGAD00001007579 -
EGAD00001007652 -
Publications Citations
Transcriptomic signatures of tumors undergoing T cell attack.
Cancer Immunol Immunother 71: 2022 553-563
5
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.
Nat Commun 14: 2023 2126
19
Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy.
J Immunother Cancer 11: 2023 e006941
3
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
Nat Commun 15: 2024 1349
4
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
Nat Commun 15: 2024 4448
1